InflaRx N.V. (IFRX) Announces Tony Gibney Joins Board of Directors

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced Mr. Tony Gibney has been appointed as a Non-Executive Director to the Board of Directors at InflaRx. Mr. Gibney is a highly experienced life sciences-focused biotech executive and former investment banker who has executed over 150 financings and M&A advisory transactions for US and European clients. Mr. Gibney's appointment was approved by InflaRx's shareholders at the 2021 annual shareholder meeting. Mr. Mark Kübler and Ms. Lina Ma were re-appointed as Non-Executive Directors to the Board of Directors.

“We are excited that Tony is joining the InflaRx board. He has tremendous experience in the biotech industry, having served as a senior executive in the financial sector and in different companies,” said Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx. “Our entire team feels fortunate about his commitment and willingness to help InflaRx with its endeavors. We are also very happy to announce the re-election of Lina Ma and Mark Kübler as board members. Both have contributed to InflaRx for many years and were instrumental in our successful IPO in 2017.”

Tony Gibney, Board member of InflaRx, said: "I am gratified to have been offered the opportunity to return to the Board of InflaRx, especially at such an important time in the Company's evolution as the leader in complement C5a inhibition. I hope that my experience in the complement arena, strategy and finance can provide incremental support to our strong Board of Directors and deep leadership team at InflaRx, as we look forward to multiple value-driving clinical readouts in indications with critical unmet needs and devastating morbidities. I am convinced that InflaRx's unique pathway can play an impactful role for patients."

Tony Gibney is currently the CFO and CBO at FogPharma, overseeing and driving the business development, strategy and finance functions of the company. Tony served as the EVP and CBO of Achillion Pharmaceuticals, Inc. from 2018 to 2020, where he was responsible for corporate and portfolio strategy, business development and corporate communications and led the successful sale of Achillion to Alexion in 2020. Before Achillion, Tony was a life sciences-focused investment banker for 24 years. From 2009 through 2018, he served as a managing director and co-head of the biotechnology investment banking team for Leerink Partners LLC. From 1999 to 2009, he was a managing director in the Life Sciences team at Merrill Lynch Inc. and executed a variety of significant financing and M&A transactions while leading the firm's East Coast biotechnology effort. Tony began his investment banking career in the Healthcare Group at Lehman Brothers in 1993. He graduated from Yale University in 1993 with a B.A. in History and Economics.

More information on InflaRx's Board is available at https://www.inflarx.de/Home/About-Inflarx/Board.html.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Tencent-backed Enflame IPO draws 6,109 times online demand
• COFE Tech Secures Pre-IPO Investment at $178 Million Valuation, Led by Aramco's Wa'ed Ventures, Aditum, Masarrah and Alyasra, Ahead of Saudi IPO